Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough. The company's business model is highly capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.

Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals Announces Last Patient Treated in Phase 2 Study of IPF and Chronic Cough

GlobeNewswire May 5, 2022

Algernon Pharmaceuticals (CSE:AGN) reports positive findings in lead chronic kidney disease drug, Repirinast

Brieanna McCutcheon  April 26, 2022

Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study

GlobeNewswire April 26, 2022

Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program

GlobeNewswire February 23, 2022

Canadian Pharma Co. Advances Chronic Cough Study

Stockhouse Editorial February 4, 2022

Algernon Pharmaceuticals (CSE:AGN) completes enrollment in its Phase 2 study of Ifenprodil

John Ballem  February 4, 2022

Algernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

GlobeNewswire February 4, 2022

Introducing Algernon Pharmaceuticals (CSE:AGN)

John Ballem  February 2, 2022

Algernon Pharmaceuticals (CSE:AGN) receives notice of allowance for Ifenprodil

Caroline Egan  January 28, 2022

Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent Application for Idiopathic Pulmonary Fibrosis

GlobeNewswire January 28, 2022

The Power Play by The Market Herald Releases Interviews with Algernon Pharmaceuticals, Newrange Gold, and Fokus Mining

Accesswire January 24, 2022

Algernon Pharmaceuticals (CSE:AGN) discloses novel salt patent strategy

John Ballem  January 24, 2022

Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property

GlobeNewswire January 24, 2022

The Power Play by The Market Herald Releases Interviews With Xali Gold, Falcon Gold, Psyched Wellness, Argentina Lithium, and Algernon Pharmaceuticals

Accesswire January 19, 2022

Algernon Pharmaceuticals (CSE:AGN) files for approval for Phase 1 DMT Human Stroke Study

John Ballem  January 19, 2022

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

GlobeNewswire January 19, 2022

The Power Play by The Market Herald Releases Interview with EarthRenew, Algernon Pharmaceuticals and Rockwell Medical

Accesswire January 14, 2022

Algernon Pharmaceuticals (CSE:AGN) receives positive feedback from the U.S. FDA for its Phase 2b Ifenprodil chronic cough study

John Ballem  January 14, 2022

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study

GlobeNewswire January 14, 2022

Algernon Pharmaceuticals Issues Compensation Options

GlobeNewswire January 4, 2022